Nexus Dx

May 22, 2018 – Hennigsdorf/San Diego – German diagnostics company sphingotec GmbH (Hennigsdorf) and Nexus Dx (San Diego) have combined their technology platforms to market sphingotec’s CE-marked acute biomarkers penKid® and bio-ADM® on Nexus’ market-validated POC testing immunoassay platform IB10 to substantially improve decision-making in emergency departments (EDs) and intensive care units (ICUs).

Top